Mon, December 2, 2024
Sun, December 1, 2024
[ Sun, Dec 01st 2024 ] - Thomas Matters
Stocking Up for Christmas?
Sat, November 30, 2024
[ Sat, Nov 30th 2024 ] - Thomas Matters
3 ISA strategies to consider
Fri, November 29, 2024
[ Fri, Nov 29th 2024 ] - Thomas Matters
OUSA: A Solid Dividend Fund
Thu, November 28, 2024
Wed, November 27, 2024
Tue, November 26, 2024
Mon, November 25, 2024

Embecta upgraded to Buy from Neutral at BTIG


//stocks-investing.news-articles.net/content/202 .. mbecta-upgraded-to-buy-from-neutral-at-btig.html
Published in Stocks and Investing on Thursday, November 28th 2024 at 2:40 GMT by Thomas Matters   Print publication without navigation

  • BTIG upgraded Embecta (EMBC) to Buy from Neutral with a $26 price target Shares gained about 30% in Tuesday trading as investors rewarded

Embecta, a medical device company focused on diabetes care, was upgraded to a "Buy" rating from "Neutral" by BTIG analyst Marie Thibault. This upgrade was based on the company's strong performance in its core business, particularly in the U.S. where it holds a significant market share in insulin syringes and pen needles. The analyst highlighted that despite potential challenges like the loss of exclusivity for some products, Embecta's strategic initiatives, including new product launches and international expansion, are expected to drive growth. Additionally, the company's efforts to manage costs and improve operational efficiency were noted as positive factors contributing to the optimistic outlook. The price target set by BTIG for Embecta's stock reflects confidence in its future profitability and market position.

Read the Full Business Insider Article at [ https://markets.businessinsider.com/news/stocks/embecta-upgraded-to-buy-from-neutral-at-btig-1034071393 ]

Publication Contributing Sources